Drugs & Targets FDA issues draft guidance on MRD and CR as primary endpoints in MM drug trials to support accelerated approval January 23, 2026Vol.52 No.03
Drugs & Targets Personalis Real-Time Variant Tracker identifies resistance mutations across several hundred clinically relevant hotspots January 23, 2026Vol.52 No.03
Drugs & Targets FDA accepts NDA for pimicotinib for treatment of tenosynovial giant cell tumor January 16, 2026Vol.52 No.02
Drugs & Targets City of Hope, Cellares collaborate to automate manufacturing of solid tumor CAR T-cell therapy January 16, 2026Vol.52 No.02
Drugs & Targets Verana Health and COTA merge to accelerate research-ready oncology real-world evidence January 16, 2026Vol.52 No.02
Drugs & Targets UAMS Winthrop P. Rockefeller Cancer Institute expands OnCore to strengthen clinical trials January 16, 2026Vol.52 No.02
Drugs & Targets FDA grants Enhertu Breakthrough Therapy designation as post-neoadjuvant therapy for HER2+ early breast cancer January 09, 2026Vol.52 No.1
Drugs & Targets China NMPA approves Pimicotinib as systemic treatment in tenosynovial giant cell tumor January 09, 2026Vol.52 No.1
